Mediceo Paltac Holdings Co Sustainability Profile
Mediceo Paltac Holdings Co., a prominent player in the pharmaceutical and healthcare distribution industry, is headquartered in Japan. Established in 1948, the company has evolved significantly, expanding its operational reach across major regions in Asia. Specialising in the distribution of pharmaceuticals, medical devices, and healthcare products, Mediceo Paltac is recognised for its commitment to quality and innovation. The company’s core offerings include a diverse range of medical supplies and consumer health products, distinguished by their reliability and adherence to stringent safety standards. With a strong market position, Mediceo Paltac Holdings has achieved notable milestones, including strategic partnerships and a robust supply chain network, solidifying its reputation as a trusted distributor in the healthcare sector.
DitchCarbon Score
How does Mediceo Paltac Holdings Co's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Mediceo Paltac Holdings Co's score of 39 is higher than 58% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Mediceo Paltac Holdings Co's reported carbon emissions
In 2023, Mediceo Paltac Holdings Co reported total carbon emissions of approximately 14,255,621,000 kg CO2e, with emissions distributed across various scopes: 28,439,000 kg CO2e (Scope 1), 46,552,000 kg CO2e (Scope 2), and 14,255,621,000 kg CO2e (Scope 3). The combined emissions from Scope 1 and Scope 2 amounted to about 74,991,000 kg CO2e. The company has not disclosed specific reduction targets or initiatives, and there are no climate pledges or SBTi targets reported. Emissions data is sourced directly from Medipal Holdings Corporation, indicating that it is not cascaded from a parent or related organization. Overall, Mediceo Paltac Holdings Co's emissions profile highlights the significant impact of Scope 3 emissions, which constitute the majority of their carbon footprint, reflecting the broader industry context where supply chain and product use emissions are critical to address for meaningful climate action.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | |
|---|---|---|---|
| Scope 1 | 32,573,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 49,959,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | 00,000,000 | 00,000,000,000 |
How Carbon Intensive is Mediceo Paltac Holdings Co's Industry?
How Carbon Intensive is Mediceo Paltac Holdings Co's Location?
Mediceo Paltac Holdings Co's Scope 3 Categories Breakdown
Mediceo Paltac Holdings Co's Scope 3 emissions, which increased significantly last year and increased significantly since 2022, demonstrating supply chain emissions tracking. Nearly all of their carbon footprint comes from suppliers and value chain emissions, representing nearly all emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 94% of Scope 3 emissions.
Top Scope 3 Categories
Mediceo Paltac Holdings Co's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Mediceo Paltac Holdings Co has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
